Identification of a Plasma Proteomic Signature for Lung Cancer

NCT01752101 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 475

Last updated 2015-01-09

No results posted yet for this study

Summary

The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary nodules.

Conditions

  • Precancerous Conditions
  • Carcinoma

Sponsors & Collaborators

  • Integrated Diagnostics

    lead INDUSTRY

Principal Investigators

  • Russell F. Hudnall · Integrated Diagnostics, Inc.

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01752101 on ClinicalTrials.gov